New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

The company’s product pipeline include ASN008, Gusacitinib and Sprifermin. Its pipeline treats atopic dermatitis, chronic hand eczema and knee osteoarthritis. Formation Bio carries out platform such ...

Other clinical trials for CHE that include agents such as Sanofi/Regneron’s dupilumab (NCT04512339), Asana BioSciences’ gusacitinib (NCT03728504), and Afecta Pharmaceuticals’ AFX5931 (NCT03703895) ...

The company currently lists three candidates in its clinical pipeline, including a SYK/JAK inhibitor called gusacitinib in phase 3 development for chronic hand eczema. There’s also a sodium ...

Gusacitinib is an oral dual JAK and spleen tyrosine kinase (SYK) inhibitor under development to treat chronic hand eczema. The investigational drug, licensed to Libertas Bio from Asana BioSciences ...

Gusacitinib hydrochloride is under clinical development by Libertas Bio and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis ...

The following is a summary of "Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study," published in the April ...